Parlux settlement
This article was originally published in The Rose Sheet
Executive Summary
Fragrance manufacturer receives $4 mil. payment as litigation settlement with one of its suppliers, Parlux Fragrances announces Oct. 7. In earlier Securities and Exchange Commission filings, Parlux said it filed a legal complaint against a component supplier in May 2001 because the company delivered faulty components for two fragrances. Costs associated with refurbishing the products were included in cost of goods for the years ended March 31, 2001 and 2002, firm adds...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.